Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
Authors
Keywords
-
Journal
npj Breast Cancer
Volume 6, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-16
DOI
10.1038/s41523-020-00197-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prevalence and mutational determinants of high tumor mutation burden in breast cancer
- (2020) R. Barroso-Sousa et al. ANNALS OF ONCOLOGY
- Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
- (2020) F. Mosele et al. ANNALS OF ONCOLOGY
- Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
- (2020) Adrienne G. Waks et al. ANNALS OF ONCOLOGY
- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- Bernard Fisher, MD: In Memoriam (1918–2019)
- (2020) Nancy E. Davidson CANCER RESEARCH
- Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis
- (2020) Meng Xu et al. Clinical Breast Cancer
- Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer
- (2020) Romualdo Barroso-Sousa et al. CLINICAL CANCER RESEARCH
- The repertoire of mutational signatures in human cancer
- (2020) Ludmil B. Alexandrov et al. NATURE
- Tissue-resident memory T cells in breast cancer control and immunotherapy responses
- (2020) Ann Byrne et al. Nature Reviews Clinical Oncology
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers
- (2020) Vivek Subbiah et al. Cancer Discovery
- Senescent stromal cells promote cancer resistance through SIRT1 loss-potentiated overproduction of small extracellular vesicles
- (2020) Liu Han et al. CANCER RESEARCH
- A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).
- (2020) Sara M. Tolaney et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors
- (2020) Johanna M. Schafer et al. Science Translational Medicine
- Re-definition of claudin-low as a breast cancer phenotype
- (2020) Christian Fougner et al. Nature Communications
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer
- (2020) Milan Radovich et al. JAMA Oncology
- Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Véronique Diéras et al. LANCET ONCOLOGY
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
- (2019) Moshe Sade-Feldman et al. CELL
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
- (2019) Ana C. Garrido-Castro et al. Cancer Discovery
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- The “Guardian of the Genome”—An Old Key to Unlock the ERCC1 Issue
- (2019) Luc Friboulet et al. CLINICAL CANCER RESEARCH
- Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
- (2019) Yi-Zhou Jiang et al. CANCER CELL
- Recent advances in triple negative breast cancer: the immunotherapy era
- (2019) Antonio Marra et al. BMC Medicine
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).
- (2019) Peter A. Fasching et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
- (2019) Adam Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic characterization of metastatic breast cancers
- (2019) François Bertucci et al. NATURE
- Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- (2019) Leonie Voorwerk et al. NATURE MEDICINE
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- The Role of Metabolic Plasticity in Blood and Brain Stem Cell Pathophysiology
- (2019) Catherine J Libby et al. CANCER RESEARCH
- Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms
- (2019) Ik Sun Kim et al. NATURE CELL BIOLOGY
- Neoantigen quality, not quantity
- (2019) Nicholas McGranahan et al. Science Translational Medicine
- LBA8_PRKEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
- (2019) P Schmid et al. ANNALS OF ONCOLOGY
- Overview of the relevance of PI3K pathway in HR-positive breast cancer
- (2019) N Vasan et al. ANNALS OF ONCOLOGY
- LBA21KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
- (2019) J Cortés et al. ANNALS OF ONCOLOGY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
- (2019) J H Park et al. ANNALS OF ONCOLOGY
- Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
- (2019) Priyanka Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting signalling pathways and the immune microenvironment of cancer stem cells — a clinical update
- (2019) Joseph A. Clara et al. Nature Reviews Clinical Oncology
- Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
- (2018) Y Bareche et al. ANNALS OF ONCOLOGY
- The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
- (2018) Vancheswaran Gopalakrishnan et al. CANCER CELL
- Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
- (2018) Charissa Kim et al. CELL
- Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer
- (2018) Daniel G. Stover et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
- (2018) Tiffany A. Traina et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells
- (2018) Shaocong Wu et al. Molecular Cancer
- Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
- (2018) Harveer Dev et al. NATURE CELL BIOLOGY
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
- (2018) Stephen J. Pettitt et al. Nature Communications
- Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers
- (2018) Daniel J. McGrail et al. Nature Communications
- Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
- (2018) Naoko Matsuda et al. JAMA Oncology
- Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
- (2018) Soo Youn Bae et al. BREAST CANCER RESEARCH AND TREATMENT
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.
- (2018) Priyanka Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).
- (2018) Rebecca Dent et al. JOURNAL OF CLINICAL ONCOLOGY
- Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
- (2018) Benjamin D. Hopkins et al. NATURE
- The shieldin complex mediates 53BP1-dependent DNA repair
- (2018) Sylvie M. Noordermeer et al. NATURE
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- The inhibitory effects of plumbagin on the NF-қB pathway and CCL2 release in racially different triple-negative breast cancer cells
- (2018) Samia S. Messeha et al. PLoS One
- Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq
- (2018) Mihriban Karaayvaz et al. Nature Communications
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy
- (2018) Fouzia Guestini et al. BREAST CANCER RESEARCH AND TREATMENT
- Identification and characterization of synthetic viability with ERCC1 deficiency in response to interstrand crosslinks in lung cancer
- (2018) Joshua Heyza et al. CLINICAL CANCER RESEARCH
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up
- (2018) Sylvia Adams et al. JAMA Oncology
- Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer
- (2018) Gerald Falchook et al. JAMA Oncology
- Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
- (2017) Aeri Kim et al. Journal of Breast Cancer
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
- (2017) Marta Łuksza et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Synthetic lethality and cancer
- (2017) Nigel J. O'Neil et al. NATURE REVIEWS GENETICS
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth
- (2017) Hyun Seung Ban et al. Cell Death & Disease
- Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
- (2017) Nadeem Riaz et al. Nature Communications
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
- (2017) David Quigley et al. Cancer Discovery
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- (2017) Kent W. Mouw et al. Cancer Discovery
- Indomethacin-based stimuli-responsive micelles combined with paclitaxel to overcome multidrug resistance
- (2017) Shuanghu Wang et al. Oncotarget
- Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
- (2017) Wouter Hendrickx et al. OncoImmunology
- A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2− advanced breast cancer (BELLE-4)
- (2016) M. Martín et al. ANNALS OF ONCOLOGY
- BRAF genomic alterations in breast cancer
- (2016) J. Albanell et al. ANNALS OF ONCOLOGY
- Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer
- (2016) U.A. Matulonis et al. ANNALS OF ONCOLOGY
- A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
- (2016) H. Bonnefoi et al. ANNALS OF ONCOLOGY
- Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
- (2016) Erik Hilborn et al. BRITISH JOURNAL OF CANCER
- Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial
- (2016) Denise A. Yardley et al. Clinical Breast Cancer
- Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
- (2016) Jeffrey R. Infante et al. CLINICAL CANCER RESEARCH
- Exploratory biomarker analysis of first-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC) from the phase 2 COLET study
- (2016) M. Wongchenko et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- What does PD-L1 positive or negative mean?
- (2016) Antoni Ribas et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions
- (2016) C. Vernieri et al. Cancer Discovery
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer
- (2015) G. Pruneri et al. ANNALS OF ONCOLOGY
- PARP inhibitors in the management of breast cancer: current data and future prospects
- (2015) Luca Livraghi et al. BMC Medicine
- Prognostic role ofPIK3CAmutations of cell-free DNA in early-stage triple negative breast cancer
- (2015) Takashi Takeshita et al. CANCER SCIENCE
- Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications
- (2015) Sherri Z. Millis et al. Clinical Breast Cancer
- Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
- (2015) R. M. Sharkey et al. CLINICAL CANCER RESEARCH
- Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease
- (2015) Eleonor Olsson et al. EMBO Molecular Medicine
- Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
- (2015) J.M. Nabholtz et al. INTERNATIONAL JOURNAL OF CANCER
- Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer
- (2015) Timothy R. Rebbeck et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
- (2015) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
- (2015) Isaac Garcia-Murillas et al. Science Translational Medicine
- Hypoxia-inducible factor-1α induces multidrug resistance protein in colon cancer
- (2015) Yingqian Lv et al. OncoTargets and Therapy
- APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity
- (2015) C. Swanton et al. Cancer Discovery
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Prostate cancer stem cells: the role of androgen and estrogen receptors
- (2015) Erika Di Zazzo et al. Oncotarget
- Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation
- (2015) Susan M. Farabaugh et al. Frontiers in Endocrinology
- Enriched CD44+/CD24− population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC)
- (2014) Fei Ma et al. CANCER LETTERS
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
- (2014) M. D. Burstein et al. CLINICAL CANCER RESEARCH
- Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients
- (2014) Jordan Madic et al. INTERNATIONAL JOURNAL OF CANCER
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
- (2014) Joyce O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
- (2014) Heae Surng Park et al. MODERN PATHOLOGY
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- An update on PARP inhibitors—moving to the adjuvant setting
- (2014) Amir Sonnenblick et al. Nature Reviews Clinical Oncology
- Targeting PI3K/Akt/mTOR Signaling in Cancer
- (2014) Camillo Porta et al. Frontiers in Oncology
- High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival
- (2013) Akimitsu Yamada et al. BREAST CANCER RESEARCH AND TREATMENT
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
- (2013) H. Masuda et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
- (2013) J. M. Balko et al. Cancer Discovery
- Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression
- (2012) Jean-Philippe Cosse et al. Anti-Cancer Agents in Medicinal Chemistry
- PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
- (2012) Roy RL Bastien et al. BMC Medical Genomics
- Role of epidermal growth factor receptor in breast cancer
- (2012) Hiroko Masuda et al. BREAST CANCER RESEARCH AND TREATMENT
- A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2
- (2012) Katharina Schlacher et al. CANCER CELL
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Mutational Processes Molding the Genomes of 21 Breast Cancers
- (2012) Serena Nik-Zainal et al. CELL
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?
- (2012) D. Yee JNCI-Journal of the National Cancer Institute
- The clonal and mutational evolution spectrum of primary triple-negative breast cancers
- (2012) Sohrab P. Shah et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance
- (2012) Justin M Balko et al. NATURE MEDICINE
- Upregulation of Trop-2 quantitatively stimulates human cancer growth
- (2012) M Trerotola et al. ONCOGENE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer
- (2011) H E Lee et al. BRITISH JOURNAL OF CANCER
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer Prognosis inBRCA1andBRCA2Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study
- (2011) Pamela J. Goodwin et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
- (2011) J. Jing et al. MOLECULAR CANCER THERAPEUTICS
- Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity
- (2010) David G. DeNardo et al. CANCER AND METASTASIS REVIEWS
- Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer
- (2010) A. A. N. Rose et al. CLINICAL CANCER RESEARCH
- Heterogeneity for Stem Cell-Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer
- (2010) S. Y. Park et al. CLINICAL CANCER RESEARCH
- CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes
- (2010) B. H. Nelson JOURNAL OF IMMUNOLOGY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
- (2009) Jorma J. de Ronde et al. BREAST CANCER RESEARCH AND TREATMENT
- The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy
- (2009) E Y Tan et al. BRITISH JOURNAL OF CANCER
- Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
- (2009) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel Two Mode-Acting Inhibitor of ABCG2-Mediated Multidrug Transport and Resistance in Cancer Chemotherapy
- (2009) Hui Peng et al. PLoS One
- Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck
- (2009) M. Persson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- How basal are triple-negative breast cancers?
- (2008) François Bertucci et al. INTERNATIONAL JOURNAL OF CANCER
- Basal-Like Breast Cancer: A Critical Review
- (2008) Emad A. Rakha et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
- (2008) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum
- (2008) Marick Laé et al. MODERN PATHOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors
- (2008) L S Steelman et al. ONCOGENE
- Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis
- (2008) P. Vaupel ONCOLOGIST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now